首页> 外文期刊>Brachytherapy >Magnetic resonance imaging-based treatment planning for prostate brachytherapy
【24h】

Magnetic resonance imaging-based treatment planning for prostate brachytherapy

机译:基于磁共振成像的前列腺近距离治疗治疗计划

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Transrectal ultrasound (TRUS) is the standard imaging modality for planning prostate brachytherapy. However, magnetic resonance imaging (MRI) provides greater anatomic detail than TRUS. We compared treatment plans generated using TRUS, endorectal coil MRI (erMRI), and standard body array coil MRI (sMRI). Methods and Materials: Treatment plans were used from patients treated with permanent, stranded-seed 125I brachytherapy in a prospective trial. All men underwent pretreatment planning based on TRUS, and all underwent erMRI before treatment and sMRI 30 days after the implant. Treatments for 20 consecutive patients were replanned on sMRI and erMRI images by investigators blinded to TRUS-based plans. Prostate volume/dimensions, radioactivity-to-prostate-volume ratio, and dosimetric parameters were compared. Results: Compared with TRUS, mean prostate volume measured by erMRI was smaller, medial-lateral diameter was larger, and anterior-posterior diameter was smaller, suggesting that the endorectal coil produced anatomic distortions. Craniocaudal prostate length was smaller on both types of MRI than on TRUS, suggesting that TRUS overestimates prostate length. Activity per volume was 7.5% lower for plans based on sMRI than on TRUS (0.901 vs. 0.974mCi/cm3, p0.001). sMRI plans had similar coverage of the planning target volume (PTV) (dose to 90% of the prostate [D90] 116.6% sMRI vs. 117.5% TRUS, p=0.526) and improved dose homogeneity (percentage of PTV receiving 150% of the prescription dose [V150] 47.4% sMRI vs. 53.8% TRUS, p=0.001 and percentage of PTV receiving 200% of the prescription dose [V200] 16.6% sMRI vs. 19.2% TRUS, p0.001). Conclusions: Staging erMRI should not be routinely used for treatment planning because it produces anatomic distortion. sMRI may have treatment planning advantages over TRUS because of superior soft-tissue delineation of the prostate and adjacent normal tissue structures. ? 2013 American Brachytherapy Society.
机译:目的:经直肠超声(TRUS)是用于计划前列腺近距离放射治疗的标准成像方式。但是,磁共振成像(MRI)比TRUS具有更大的解剖学细节。我们比较了使用TRUS,直肠内线圈MRI(erMRI)和标准人体阵列线圈MRI(sMRI)生成的治疗计划。方法和材料:在一项前瞻性试验中,采用接受永久性,滞留种子125I近距离放射治疗的患者的治疗计划。所有男性均接受了基于TRUS的治疗前计划,所有患者在治疗前和植入后30天进行sMRI。由不了解基于TRUS计划的研究人员在sMRI和erMRI图像上重新计划了20位连续患者的治疗方案。比较了前列腺的体积/尺寸,放射性与前列腺的体积比以及剂量学参数。结果:与TRUS相比,通过erMRI测量的平均前列腺体积更小,内侧直径更大,而前后直径更小,表明直肠内线圈产生了解剖畸变。两种类型的MRI的颅尾前列腺长度均比TRUS小,提示TRUS高估了前列腺长度。基于sMRI的计划的每体积活度比基于TRUS的计划低7.5%(0.901对0.974mCi / cm3,p <0.001)。 sMRI计划对计划目标体积(PTV)的覆盖率相似(占前列腺90%的剂量[D90] 116.6%sMRI与117.5%TRUS,p = 0.526),并且剂量均一性得到改善(PTV接受150%前列腺癌的百分比)处方剂量[V150] sMRI为47.4%,而TRUS为53.8%,p = 0.001,接受200%处方剂量[V200] sMRI为16.2%TRUS的PTV的百分比为16.2%,p <0.001)。结论:分期erMRI不应常规用于治疗计划,因为它会产生解剖畸变。 sMRI可能具有优于TRUS的治疗计划优势,因为前列腺和邻近正常组织结构具有出色的软组织轮廓。 ? 2013美国近距离放射治疗学会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号